At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
Everolimus (RAD001)drug
Likely dose
Everolimus (RAD001) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Everolimus (RAD001) for Hodgkin Lymphoma. Completed, enrolled 57 participants across 16 sites.
Detailed Summary
This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartDec 2009
Primary CompletionNov 2014
TodayJul 2026
First PostedDec 1, 2009
Enrollment StartDec 1, 2009
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 16.6 years ago
Interventions
Everolimus (RAD001)drug
Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.